Wells Fargo Lowers Tandem Diabetes Care Price Target to $13.00

Wells Fargo analyst Larry Biegelsen has lowered the price target for Tandem Diabetes Care (TNDM) from $20.00 to $13.00 USD, a 35% decrease. This change reflects evolving perspectives on the firm's financial outlook and performance. Tandem Diabetes designs and markets insulin pumps for diabetes patients, with nearly three-quarters of revenue derived from the US. The average target price for TNDM is $29.05, with a high estimate of $75.00 and a low estimate of $13.00.

In the latest developments, Wells Fargo analyst Larry Biegelsen has lowered the price target for Tandem Diabetes Care (TNDM) from $20.00 to $13.00 USD, a 35% decrease. This adjustment reflects a shift in market sentiment and evolving perspectives on the company's financial outlook and performance [1].

Tandem Diabetes Care, a global insulin delivery and diabetes technology company, designs and markets durable insulin pumps for diabetes patients. The company's revenue is predominantly derived from the United States, with nearly three-quarters of its total sales coming from this market. The recent financial results indicate that the company achieved record second-quarter sales both in the United States and internationally, demonstrating year-over-year and sequential gross margin improvement [2].

The average target price for TNDM is currently $29.05, with a high estimate of $75.00 and a low estimate of $13.00. Analysts have provided diverse perspectives, with some maintaining their bullish stance while others have become more cautious. The latest update from Wells Fargo reflects a more bearish outlook, with the price target being significantly reduced to $13.00.

Key analysts have made adjustments to their ratings and price targets in response to recent market dynamics and company performance. For instance, Matt O'Brien of Piper Sandler lowered the rating from Neutral to Low and reduced the price target from $30.00 to $14.00, reflecting a more conservative view [1]. Similarly, Joanne Wuensch of Citigroup lowered the rating from Neutral to Sell and reduced the price target from $24.00 to $14.00, indicating a significant change in sentiment [1].

These changes underscore the importance of staying informed about analyst ratings and their implications for stock performance. Analysts provide valuable insights into the financial health and future prospects of companies, and their adjustments can signal shifts in market sentiment and expectations.

References:
[1] https://www.benzinga.com/insights/analyst-ratings/25/08/46961056/forecasting-the-future-4-analyst-projections-for-tandem-diabetes-care
[2] https://www.stocktitan.net/news/TNDM/tandem-diabetes-care-announces-second-quarter-2025-financial-results-1vi3a9qlroup.html